BioWorld

Sep. 15, 2003

View Archived Issues

Neurocrine Biosciences Brings In $200M In Oversold Public Offering

Marching ahead with its non-benzodiazepine insomnia drug indiplon, Neurocrine Biosciences Inc. said it priced an offering of 3.75 million shares at $53 per share, for net proceeds of about $200 million. (BioWorld Today) Read More

Tercica, Armed With Genentech Technology, Seeks $86.25M IPO

Read More

Ligand Gains $47M In Private Sale To Expand Commercial Activities

Read More

Alexion Raises $44 Million For Development Of Pipeline Drugs

Read More

Axonyx Placement Garners $25M For Second Phase III

Read More

Other News To Note

Read More